Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Angewandte Chemie (International Ed. in English)|November 11, 2021
Tunable Amine-Reactive Electrophiles for Selective Profiling of LysineKuei-Chien Tang, Jian Cao, Lisa M Boatner, et al.
Cancer Research Communications|March 27, 2023
Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast CancerRobert B Jones, Jonathan Farhi, Miranda Adams, et al.
Annales De Biologie Clinique|August 7, 2018
[Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis]Jérôme Debus, Pierre Lemaire, Mustafa Alani, et al.
European Journal of Haematology|April 18, 2020
R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory studyCarole Lacout, Corentin Orvain, Valérie Seegers, et al.
Hematological Oncology|July 23, 2016
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphomaKamel Laribi, Adrien Tempescul, Habib Ghnaya, et al.
Annals of Hematology|August 10, 2018
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphomaJonathan Farhi, Kamel Laribi, Corentin Orvain, et al.
Transplantation|March 8, 2016
Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive CareCorentin Orvain, Francois Beloncle, Jean-Francois Hamel, et al.
Annals of Hematology|May 3, 2018
Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essenceCorentin Orvain, Francois Beloncle, Jean-Francois Hamel, et al.
Cancers|July 2, 2021
Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal InvolvementMélanie Mercier, Corentin Orvain, Laurianne Drieu La Rochelle, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotypeKirti Sad, Celina Y Jones, Dorelle V Fawwal, et al.
Pageof 3